Class II-associated invariant chain peptide as predictive immune marker in minimal residual disease in acute myeloid leukemia

  • Oncoimmunology. 2015 Jan 7;3(12):e941737. doi: 10.4161/21624011.2014.941737.
Marvin M van Luijn  1 ,  Willemijn van den Ancker  2 ,  S Marieke van Ham  3 ,  Arjan A van de Loosdrecht  2
Affiliations
  • 1. Department of Hematology; Cancer Center Amsterdam; VU Institute for Cancer and Immunology; VU University Medical Center ; Amsterdam, The Netherlands ; Department of Immunology; Erasmus MC University Medical Center ; Rotterdam, The Netherlands.
  • 2. Department of Hematology; Cancer Center Amsterdam; VU Institute for Cancer and Immunology; VU University Medical Center ; Amsterdam, The Netherlands.
  • 3. Department of Immunopathology; Sanquin Research and Landsteiner Laboratory; Academic Medical Center; University of Amsterdam ; Amsterdam, The Netherlands.
PMID: 25964856 DOI: 10.4161/21624011.2014.941737
Abstract

The majority of patients with acute myeloid leukemia (AML) reach complete remission after high-dose chemotherapy. Still, half of these patients experience a relapse due to presence of minimal residual disease (MRD). Here we discuss the poor prognostic role of class II-associated invariant chain peptide (CLIP) expression on residual leukemic cells.

Keywords
CD4+ T cells; HLA; immune escape; leukemia-associated phenotype; minimal residual disease.
Products